On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Okayama University Hospital

InstitutionResearch output, impact & collaborations

Okayama University Hospital is a institution indexed in ScholarIQ from OpenAlex.

What is known about Okayama University Hospital?

ScholarIQrecord summary

Okayama University Hospital is a research organisation in Okayama, JP. OpenAlex records 8,899 works and 361,921 citations for it. 1,883 researchers list it as their most recent affiliation.

How many works does Okayama University Hospital have?

ScholarIQindexed works

Okayama University Hospital has 8,899 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Okayama University Hospital have?

ScholarIQcitation count

Okayama University Hospital has 361,921 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Okayama University Hospital?

ScholarIQresearcher count

Okayama University Hospital has 1,883 researchers in the ScholarIQ index.

What is the average h-index at Okayama University Hospital?

ScholarIQavg h-index

Okayama University Hospital has an average h-index of 48 in OpenAlex.

What is the ROR of Okayama University Hospital?

ScholarIQror

The ROR for Okayama University Hospital is on the source record.

What is the OpenAlex record for Okayama University Hospital?

ScholarIQopenalex

The OpenAlex for Okayama University Hospital is on the source record.

Who are the most-cited researchers behind Okayama University Hospital?

ScholarIQtop researchers by citations
1
Hirofumi Makino · Chronic Kidney Disease and Diabetes
980 works38,753 citations
2
Katsuyuki Hotta · Lung Cancer Treatments and Mutations
640 works32,122 citations
3
Kazuyuki Matsumoto · Pancreatic and Hepatic Oncology Research
440 works3,080 citations
4
Shigeru Horiguchi · Pancreatic and Hepatic Oncology Research
181 works1,707 citations

What are the most-cited papers on Okayama University Hospital?

ScholarIQmost cited works
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer
New England Journal of Medicine. 201610,184 CitationsOPEN ACCESS
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
The Lancet. 20192,246 Citations
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Jan J. Weening, Vivette D. D’Agati, Melvin M. Schwartz, Surya V. Seshan, Charles E. Alpers, Gerald B. Appel, James E. Balow, Jan A. Bruijn, Terence Cook, Franco Ferrario, Agnes B. Fogo, Ellen M. Ginzler, Lee A. Hebert, Gary S. Hill, Prue Hill, J. Charles Jennette, Norella Kong, Philippe Lesavre, Michael D. Lockshin, Lai‐Meng Looi, Hirofumi Makino, Luiz A. Moura, Michio Nagata
Journal of the American Society of Nephrology. 20042,006 CitationsOPEN ACCESS
The classification of glomerulonephritis in systemic lupus erythematosus revisited
Jan J. Weening, ON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis, Vivette D. D’Agati, Melvin M. Schwartz, Surya V. Seshan, Charles E. Alpers, Gerald B. Appel, James E. Balow, Jan A. Bruijn, Terence Cook, Franco Ferrario, Agnes B. Fogo, Ellen M. Ginzler, L Hebert, Gary S. Hill, Prue Hill, J. Charles Jennette, Norella Kong, Philippe Lesavre, Michael D. Lockshin, Lai‐Meng Looi, Hirofumi Makino, Luiz A. Moura, Michio Nagata
Kidney International. 20041,665 CitationsOPEN ACCESS
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura
The Lancet. 2017921 Citations

How much of the research on Okayama University Hospital is open access?

ScholarIQopen access share
50%OPEN ACCESS
Gold
0%
Green
33%
Hybrid
0%
Bronze
17%
Closed
50%

Related on ScholarIQ

470M+ articles · 14-day free trial